The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.
作者信息
Aartsma-Rus Annemieke, Corey David R
机构信息
Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Department of Pharmacology, UT Southwestern Medical Center, Dallas, Texas.
出版信息
Nucleic Acid Ther. 2020 Apr;30(2):67-70. doi: 10.1089/nat.2020.0845. Epub 2020 Feb 11.
Abstract
摘要
相似文献
1
The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.
Nucleic Acid Ther. 2020 Apr;30(2):67-70. doi: 10.1089/nat.2020.0845. Epub 2020 Feb 11.
2
Golodirsen for Duchenne muscular dystrophy.
Drugs Today (Barc). 2020 Aug;56(8):491-504. doi: 10.1358/dot.2020.56.8.3159186.
3
Designing Effective Antisense Oligonucleotides for Exon Skipping.
Methods Mol Biol. 2018;1687:143-155. doi: 10.1007/978-1-4939-7374-3_10.
4
FDA-Approved Oligonucleotide Therapies in 2017.
Mol Ther. 2017 May 3;25(5):1069-1075. doi: 10.1016/j.ymthe.2017.03.023. Epub 2017 Mar 31.
5
Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
Future Med Chem. 2015;7(13):1631-5. doi: 10.4155/fmc.15.116. Epub 2015 Oct 1.
6
Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Methods Mol Biol. 2018;1687:123-141. doi: 10.1007/978-1-4939-7374-3_9.
7
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
Nucleic Acid Ther. 2017 Feb;27(1):1-3. doi: 10.1089/nat.2016.0657. Epub 2016 Dec 8.
8
Casimersen (Amondys 45) for Duchenne muscular dystrophy.
Med Lett Drugs Ther. 2021 Jun 28;63(1627):e104-e105.
9
Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Expert Rev Mol Med. 2019 Oct 2;21:e5. doi: 10.1017/erm.2019.5.
10
PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
Methods Mol Biol. 2018;1687:185-192. doi: 10.1007/978-1-4939-7374-3_13.
引用本文的文献
1
The RNA revolution in medicine: from gene regulation to clinical therapeutics.
Anim Cells Syst (Seoul). 2025 Aug 25;29(1):523-543. doi: 10.1080/19768354.2025.2548253. eCollection 2025.
2
Development of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation.
Int J Mol Sci. 2025 Aug 12;26(16):7774. doi: 10.3390/ijms26167774.
3
Duchenne Muscular Dystrophy: Integrating Current Clinical Practice with Future Therapeutic and Diagnostic Horizons.
Int J Mol Sci. 2025 Jul 14;26(14):6742. doi: 10.3390/ijms26146742.
4
High-Resolution HPLC for Separating Peptide-Oligonucleotide Conjugates.
ACS Omega. 2025 Apr 30;10(20):20578-20584. doi: 10.1021/acsomega.5c01308. eCollection 2025 May 27.
5
Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model.
Int J Mol Sci. 2025 Mar 27;26(7):3098. doi: 10.3390/ijms26073098.
6
Cell-penetrating peptide-conjugated, splice-switching oligonucleotides mitigate the phenotype in / double deficient X-linked agammaglobulinemia model.
RSC Chem Biol. 2025 Mar 31;6(5):761-771. doi: 10.1039/d4cb00312h. eCollection 2025 May 8.
7
RNA therapeutics in cardiovascular medicine.
Curr Opin Cardiol. 2025 May 1;40(3):139-149. doi: 10.1097/HCO.0000000000001210. Epub 2025 Feb 18.
8
Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy.
J Muscle Res Cell Motil. 2025 Jan 30. doi: 10.1007/s10974-024-09688-2.
9
Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy.
Cell Rep Med. 2025 Jan 21;6(1):101901. doi: 10.1016/j.xcrm.2024.101901. Epub 2025 Jan 9.
10
Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells.
Skelet Muscle. 2024 Nov 29;14(1):28. doi: 10.1186/s13395-024-00360-4.
本文引用的文献
1
Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy.
Mol Ther Nucleic Acids. 2020 Mar 6;19:371-383. doi: 10.1016/j.omtn.2019.11.020. Epub 2019 Nov 27.
2
Viltolarsen for the treatment of Duchenne muscular dystrophy.
Drugs Today (Barc). 2019 Oct;55(10):627-639. doi: 10.1358/dot.2019.55.10.3045038.
3
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases.
EBioMedicine. 2019 Jul;45:630-645. doi: 10.1016/j.ebiom.2019.06.036. Epub 2019 Jun 27.
4
Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.
J Neuromuscul Dis. 2019;6(2):213-225. doi: 10.3233/JND-180351.
5
Evidence-Based Consensus and Systematic Review on Reducing the Time to Diagnosis of Duchenne Muscular Dystrophy.
J Pediatr. 2019 Jan;204:305-313.e14. doi: 10.1016/j.jpeds.2018.10.043.
6
Why dystrophin quantification is key in the eteplirsen saga.
Nat Rev Neurol. 2018 Aug;14(8):454-456. doi: 10.1038/s41582-018-0033-8.
7
Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
Neurology. 2018 Jun 12;90(24):e2146-e2154. doi: 10.1212/WNL.0000000000005680. Epub 2018 May 11.
8
Arginine-rich membrane-permeable peptides are seriously toxic.
Pharmacol Res Perspect. 2017 Oct;5(5). doi: 10.1002/prp2.334.
9
Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.
Nucleic Acid Ther. 2017 Oct;27(5):251-259. doi: 10.1089/nat.2017.0682. Epub 2017 Aug 10.
10
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
Nucleic Acid Ther. 2017 Feb;27(1):1-3. doi: 10.1089/nat.2016.0657. Epub 2016 Dec 8.
Zotero 插件